Cimzia (certolizumab pegol) is an immunosuppresant, approved by the FDA for the treatment of Crohn's disease, rheumatoid arthritis, and juvenile arthritis. It is administered through a subcutaneous injection.
The most common side effects of Cimzia are headache, upper respiratory infections, abdominal pain, injection site reactions and nausea. Patients taking Cimzia are at increased risk for serious adverse effects, including serious infections that can lead to hospitalization or death. Because Cimzia affects the immune system, it can lower the body's ability to fight infections, such as tuberculosis and other opportunistic infections. Cimzia is a blocker of TNF (tumor necrosis factor) and may cause lymphomas (a form of cancer) and other malignancies.
Recently, Cimzia was given a Black Box Label Warning by the FDA. The Black Box Warning is the strongest warning label a drug can have applied to it. Drugs that carry a high risk of serious side effects or potentially deadly adverse reactions are given this warning. This label is given only after medical studies have indicated that there are serious risks associated with the side effects of the medication.
Cimzia Linked to Life-Threatening Cancer Risk Among Children, Young Adults
Cimzia (certolizumab pegol) is an autoimmune disorder drug belonging to a family of drugs known as tumor necrosis factor (TNF) inhibitors. Recently, Cimzia, along with several other TNF blockers, were linked to an increased risk of cancer among patients taking the drug, specifically among young adults and children. Food and Drug Administration (FDA) launched an investigation into the TNF blockers after at least 30 cases of cancer among children consuming the drugs were reported during a ten-year period from 1998 to 2008, according to a September 2008 news article from Reuters .
read more
Living With Crohn's Disease
Crohn's disease is a physical disorder in which the inflammation of the digestive system occurs. The Crohn's and Colitis Foundation of America (CCFA) has researched the potential causes of Crohn's disease and have found that while more research is necessary as to the specific reasons behind the condition, the following are factors that may contribute to an individual developing the condition: genes (a family's history of illnesses) an individuals immune system foreign substances such as antigens in the environment According to the CCFA, many scientists believe that "the interaction of an outside agent (such as a virus or bacterium) with the body's immune system may trigger the disease." Unfortunately, if an individual has a weakened immune system and they also have a family history of Crohnís disease or ulcerative coliti , they are at a high risk for developing the disease. Both males and females are equally affected and individuals between the ages of 15 and 35 make up most of the population of Crohn's disease sufferers , between 500,000 and 1 million Americans.
read more
View the Cimzia Law Articles page here
Cimzia News Articles
2010Äê¶È»ñÅúµÄС·Ö×ÓÒ©ÎïÅ̵ã-ÉúÎïÒ½Ò©²úÒµ - ÉúÎï¹È
Article > NICE turns down B-MS' Orencia as second-line RA option
View the
Cimzia News Articles
page here
Cimzia Newsfeeds
FDA Continues Review of Cancer Risk Associated with TNF blockers, Azathioprine, and/or Mercaptopurine
FDA Warns Again of Lymphoma Risk With TNF Blockers in Teens
View the
Cimzia Newsfeeds
page here